# Safety and Immunogenicity in Age De-Escalation of PfSPZ Vaccine in Tanzanian Adults, Children, and Infants

> **NCT02613520** · PHASE1 · COMPLETED · sponsor: **Sanaria Inc.** · enrollment: 105 (actual)

## Conditions studied

- Malaria

## Interventions

- **BIOLOGICAL:** PfSPZ Vaccine
- **OTHER:** Normal Saline
- **BIOLOGICAL:** PfSPZ Challenge (for CHMI)

## Key facts

- **NCT ID:** NCT02613520
- **Lead sponsor:** Sanaria Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2017-02
- **Final completion:** 2017-03
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2018-10-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02613520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02613520, "Safety and Immunogenicity in Age De-Escalation of PfSPZ Vaccine in Tanzanian Adults, Children, and Infants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02613520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*